The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Fintel reports that on July 21, 2025, Needham downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Hold to ...

Fintel reports that on July 21, 2025, Leerink Swann downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

H.C. Wainwright sets a rare $0 target for Sarepta Therapeutics amid FDA scrutiny over its Duchenne muscular dystrophy gene therapy Elevidys. Read more here.

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and ...

US stocks closed mixed on Monday, but the Nasdaq Composite and S&P 500 managed to notch fresh records. Wall Street began a ...

FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...

Investing.com -- Sarepta Therapeutics came under pressure after two brokerages slashed their price targets and downgraded the stock, flagging mounting safety, regulatory, and credibility concerns ...